Overview

Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis

Status:
Active, not recruiting

Trial end date:
2022-12-15

Target enrollment:

Participant gender:

Summary

This is a multicenter, national, nonrandomized, phase II trial in subjects with nonsquamous NSCLC patients that have untreated asymptomatic BM. A pre-screening period using brain MRI for patients diagnosed with advanced non-squamous NSCLC EGFR/ALK wild type and ECOG PS 0-1 will be crucial to identify patients with asyntomatic BM. Forty patients will be recruited.

Phase:

Phase 2

Details

Lead Sponsor:

Spanish Lung Cancer Group

Treatments:

Antibodies, Monoclonal
Atezolizumab
Carboplatin
Pemetrexed